Q2 2026 earnings call recap: 17% core revenue growth, 18% margin, raised FY26 guidance, AI fraud wins, and Q3 outlook—read key takeaways.

BILL stock jumps 30% on report Hellman & Friedman is in talks to buy Bill Holdings after strong Q2 FY2026 results and guidance.

Rejuvant’s CaAKG Supplement Becomes Core Requirement in Lionheart’s KLOTHO-UP™ Study and Klotho Wellness Program ...

BILL Holdings (BILL) shares jumped 14% in Friday morning trading after the small-business-focused financial operations ...

Dietary supplements are not approved for safety or efficacy by the U.S. Food and Drug Administration (FDA), and ingredients ...

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrum Launch readiness ...